Calculation of Organs Doses and Secondary Cancer Risk during Mantle Field Radiotherapy for Hodgkin’s Lymphoma

Occurrence of radiation-induced secondary cancer risk following mantle field radiotherapy for Hodgkin's lymphoma (HL) patients with long survival demands well-established radiotherapy strategy. Organs doses and resulted secondary cancer risk due to out-of field photons were calculated during mantle field radiotherapy for Hl patient. The male and female mathematical phantom of the Oak Ridge National Laboratory (ORNL) and validated 6MV photon beam of a Varian 2300 C/D were modeled by MCNPX 2.4.0 MC code. Using suitable lungs and thyroid shields for AP and PA fields, the organ specific absorbed doses, effective dose, and secondary cancer risk were calculated following to mantle field radiotherapy for HL. Among the out-of-field organs, the nose, eyes, head and neck's skins and sinuses have the higher received doses. The total effective doses and secondary cancer risk for a male and female were estimated to be 199, 234 mSv and 1.72, 1.87 respectively. During mantle field radiotherapy for Hodgkin's lymphoma, accurately estimations of organs dose near to the field's edge and suitable shielding of critical in-field organs are crucial factor to establish an optimal treatment plan.